Evolution The pharmaceutical market uses outsourcing services from providers in the form of contract research organizations (CROs) and contract manufacturing organizations. In recent years, the concept of a comprehensive single-source provider from drug development through commercial manufacture has emerged. This concept has been implemented by providers known today as contract development and manufacturing organizations (CDMOs).  Before the financial crisis of 2007–2008, 75\% of the candidate that outsourced services were small and mid-sized biotechnology and pharmaceutical companies. Following the financial crash in 2008 the CMO industry started to be funded by private equity as a result of a substantial growth and a more qualified management. The one-stop CDMO concept could be the direction the industry is heading by offering the whole spectrum of development services (e.g. development, production and analysis). The acquisitions that have been finalized in 2017 in CMO and CDMO industry brought some of these companies to a level that allows them to compete with global bio/pharma companies. The value of the mergers and acquisitions in 2017 was likely to exceed $20 billion, below are some examples of these M&A: Lonza Group – Capsugel: their manufacturing scale combined together is equivalent to a $25 billionbio/pharma company Thermo Fisher Scientific – Patheon: that merge allows Patheon to improve its portfolio with clinical development, manufacturing, and packaging services in order to make them a one-stop supplier The Carlyle Group – AMRI Global: this acquisition will help AMRI to be more financial savvy and operational focus  Another aspect of these acquisition is coming from CMO that are acquiring manufacturing site from bio/pharma companies. Some example could be from some acquisition of Avara Pharmaceutical: Novartis Sandoz site in Boucherville – Canada in 2018  Glaxo Smith Kline site in South Carolina – US in 2018 AstraZeneca site in Reims – France in 2017 Pfizer site in Liscate – Italy in 2017
Overview The pharmaceutical market uses outsourcing services from providers in the form of contract research organizations (CROs) and contract manufacturing organizations. In recent years, the concept of a comprehensive single-source provider from drug development through commercial manufacture has emerged. This concept has been implemented by providers known today as contract development and manufacturing organizations (CDMOs). History Before the financial crisis of 2007–2008, 75\% of the candidate that outsourced services were small and mid-sized biotechnology and pharmaceutical companies. Following the financial crash in 2008 the CMO industry started to be funded by private equity as a result of a substantial growth and a more qualified management. The one-stop CDMO concept could be the direction the industry is heading by offering the whole spectrum of development services (e.g. development, production and analysis). The acquisitions that have been finalized in 2017 in CMO and CDMO industry brought some of these companies to a level that allows them to compete with global bio/pharma companies. The value of the mergers and acquisitions in 2017 was likely to exceed $20 billion, below are some examples of these M A: Another aspect of these acquisition is coming from CMO that are acquiring manufacturing site from bio/pharma companies. In 2017, Pfizer established a manufacturing site in Liscate, Italy, which was followed that same year by AstraZeneca in Reims, France. Novartis Sandoz acquired a site in Boucherville , Canada in 2018 , as well as Glaxo Smith Kline , which began manufacturing out of South Carolina in the United States. Samsung Biologics built three manufacturing plants with a capacity of more than 360,000 liters, making it the world's largest contract-based manufacturer in the biopharmaceutical sector at a single site as of 2018.
R
Evolution
Overview
A
History
R
$20 billion, below are some examples of these M&A: Lonza Group – Capsugel: their manufacturing scale combined together is equivalent to a $25 billionbio/pharma company Thermo Fisher Scientific – Patheon: that merge allows Patheon to improve its portfolio with clinical development, manufacturing, and packaging services in order to make them a one-stop supplier The Carlyle Group – AMRI Global: this acquisition will help AMRI to be more financial savvy and operational focus
$20 billion, below are some examples of these M
A
A:
D
Some example could be from some acquisition of Avara Pharmaceutical:
R
Novartis Sandoz
In 2017, Pfizer established a manufacturing site in Liscate, Italy, which was followed that same year by AstraZeneca in Reims, France. Novartis Sandoz acquired a
R
–
,
A
, as well as
R
site in South Carolina – US in 2018 AstraZeneca site in Reims – France in 2017 Pfizer site in Liscate – Italy in 2017
, which began manufacturing out of South Carolina in the United States. Samsung Biologics built three manufacturing plants with a capacity of more than 360,000 liters, making it the world's largest contract-based manufacturer in the biopharmaceutical sector at a single site as of 2018.